Stem cell “secretome” is the latest advancement in regenerative medicine. Will it become the heart of tissue regeneration? SmartTRAK interviewed Dr. Robert Keller, Ph.D, Chief Science Officer of Axolotl Biologix to learn more about the Company’s platform and future plans.

The core of regenerative medicine and leveraging the abilities of stem cells and their products to repair diseased or damaged tissues has focused in two main areas, harvesting progenitor cells and the “paracrine effect” of the stem cell secretome.

Recent studies suggest that the benefits of stem cell therapy and the underlying mechanism of repair might relate more to a paracrine modulatory effect rather than the replacement of damaged cells at the site. The secreted factors from the transplanted stems cells have been shown to trigger the patient's own cells to repair the tissue themselves.

One company that is harnessing the power of the stem cell secretome is Axolotl Biologics. Started in 2016, Axolotl Biologics offers human amnion-derived mesenchymal stromal cell (hAMSCs) conditioned medium that contains hAMSCs paracrine factors which can be used in various applications in orthopedics, wound care, pain management, ophthalmology, cardiovascular and cosmetics.

At the 6th ICRS Summit, Bio-Orthopaedics in Sports Medicine, held in San Diego, January 17 and 18, 2019, SmartTRAK caught up with Axolotl Biologix’ Chief Science Officer, Robert Keller, Ph.D. to discuss regenerative medicine and the Company’s progress.

Click on the video below to view the fascinating interview,  scroll down to read a transcript of the interview or download a PDF of the interview by clicking the link below.

Well-rounded portfolios leading to strong Q318 for Soft Tissue Fixation

SmartTRAK reports that the continued rounding out of portfolios is leading to some commoditization in the market, but also allowing companies to capitalize on the strength of their sales forces in new portions of the Sports Medicine Market. High single and double-digit growth reported...

Among the many topics covered in the Q318 Soft Tissue Fixation Market Recap are:

Robotics Contributing to Above Market Growth Through Implant Pull-Through

Robotics continued to be a hot topic in orthopedics in Q318 with some companies and surgeons projecting that robotics will become standard-of-care in orthopedic procedures in the next 3-5 years...

Among the many interesting topics covered in SmartTRAK's Q318 CAS Ortho Market Recap are:

Tough comps, supply disruption and the ever-present pricing pressure impacts growth

SmartTRAK reports that the WW Trauma Market experienced a downturn in Q3, posting only +1.1% (reported) growth. The US Market was up +2.0% YoY, but is down sequentially compared to last quarter’s +5.0% gains...

Among the many topics covered in SmartTRAK's Q318 Trauma Market Recap are:

The Spine hardware market appears to be stabilizing.

SmartTRAK reports that results from a recent Leerink MEDACorp survey suggest that the US Spine market may be turning the corner, with hospital administrators reporting slightly improved case volume growth of 0.9% for Q318 vs 0.7% for Q2. This is consistent with Leerink’s intra-quarter checks and conversations at the North American Spine Society (NASS) 2018 Annual Meeting that the market...

Among the many topics covered in the Q318 Spine Market Recap are:

BioMedGPS is proud to feature the top 2018 news and analysis from SmartTRAK’s team of domain experts in the orthopedics, wound care, and neuro therapies markets.

IRVINE, CA (PRWEB) JANUARY 02, 2019

Acquisitions and Partnerships are Highpoints in Q318

SmartTRAK reports that the US OrthoBio Market (comprised of Bone Replacement, Cartilage, Soft Tissue and Meniscus) is growing at 4.1% YTD. For Q318, there were no surprises and the segment reached...

Among the many topics covered in the Q318 OrthoBio Market Recap are:

SmartTRAK was excited to attend the 2018 Orthopaedic Summit (OSET), on December 5-8 at the Bellagio in Las Vegas, Nevada. And, our very own Kristina Meyer, Senior Analyst, Sports Medicine, landed on the front of the OSET banners. We always knew Kristina was a pretty big deal!  Thanks OSET for the coverage.

Pricing pressure continues to dampen the US Joint Fluid market, which experienced a double-digit decline of -9.9% according to SmartTRAK's Financial Dashboard results. While the market continues to expand in terms of the number of patients treated, ASPs have steadily eroded over the past three quarters since the Anthem non-coverage decision kicked in earlier this year. Year-to-date, the US Joint Fluid market slowed significantly, posting negative growth according to SmartTRAK estimates...